Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...

A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...

The European Union’s health regulator on Friday rejected Eli Lilly’s (LLY) Alzheimer’s drug, Kisunla, citing risks of brain ...

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...

Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now advisers to the European Medicines Agency say it shouldn't be approved.

Eli Lilly (LLY) stock in focus as an expert panel of the EU drug regulator declines to endorse its Alzheimer's drug Kisunla.

The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...

The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...

Investing in stocks remains one of the best ways to accumulate capital over long periods. Companies that can last -- and ...

The trial results are critical, as it brings Eli Lilly's pill one step closer to becoming a new, needle-free alternative for ...

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...